ACTRN12608000248369CompletedPhase 3
The role of Gabapentin in the treatment of refractory chronic dry cough: A randomised double-blind placebo-controlled study.
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Enrollment
- 56
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomised controlled trial
- Primary Purpose
- Treatment
- Masking
- Blinded (masking used)
Eligibility Criteria
- Ages
- 18 Years to 80 Years (—)
- Sex
- All
Inclusion Criteria
- •Persistent non-productive cough of more than 8 weeks duration,
- •Male or female between ages of 18 and 80 years,
- •Non-smoker or ex-smoker with less than 10 pack years,
- •To have been well during the 4 weeks prior to study entry,
- •Informed consent obtained.
Exclusion Criteria
- •Productive cough,
- •Current smoker,
- •Smoking history >10 pack years,
- •Pregnancy/breast feeding,
- •Other respiratory disease, eg: bronchiectasis, COPD.
- •Inability to attend study visits
- •Respiratory tract infection during month prior to randomisation
- •Impaired liver function at Visit 1 as shown by Aspartate aminotransferase (AST), an enzyme normally present in liver and heart cells and alanine aminotransferase (ALT). If the liver is injured, the liver cells spill the enzymes into blood, raising the enzyme levels in the blood and signaling liver damage.
- •Therefore, an AST, ALT, alkaline phosphatase or total bilirubin greater than 2 times the upper limit of normal will exclude a participant.
Investigators
Similar Trials
Completed
Phase 2
The efficacy of Gabapentin in the management of post menopausal sleep disorder and life qualitySleep disturbance.Nonorganic sleep disordersIRCT201304184686N3Arak University Medical of Sciences270
Completed
Phase 2
The use of gabapentin in the treatment ofkeratoconusPostoperative painC23.550.767.700RBR-23r5mcniversidade do Oeste de Santa Catarina
Completed
Not Applicable
A study to evaluate the usefulness of drug Gabapentin in reducing adverse symptoms after brain injuryCTRI/2020/04/024537DR SURUCHI60
Not yet recruiting
Phase 3
The efficacy of Gabapentin in chronic refractory cough in Interstitial Lung DiseaseCTRI/2024/07/071040one
Recruiting
Phase 4
Gabapentin as symptomatic therapy of cerebellar ataxia in degenerative and inflammatory CNS-diseaseG11.2G31.9G35Late-onset cerebellar ataxiaDegenerative disease of nervous system, unspecifiedMultiple sclerosisDRKS00000269FakultätsleitungCharité - Universitätsmedizin Berlin72